Background and Purpose:
Recurrent malignant gliomas have a very poor prognosis. This trial aimed to evaluate the benefits of reirradiation in case of recurrent glioblastoma multiforme (GBM) using hypofractionated stereotactic radiotherapy (hFSRT) after primary high-dose percutaneous irradiation.
Patients and Methods:
Between 1998 and 2008, 53 patients with recurrent GBM were treated by hFSRT based on CT and MR imaging. At the time of recurrence, a median total dose of 30 Gy (20–60 Gy) was delivered in median fractions of 3 Gy/day (2–5Gy).
Results:
The reirradiation was well tolerated (no acute or late toxicity > grade 2), despite the relatively large median tumor volume (35.01 ml). Karnofsky Performance Score was the strongest predictor for survival after reirradiation (p = 0.0159). Tumor volume (p = 0.4690), patient age (p = 0.4301), second operation (p = 0.6930), and chemotherapy (p = 0.1466) at the time of reirradiation did not affect survival. After hFSRT, the median survival was 9 months, and the 1-year progression-free survival (PFS) amounted to 22%.The median overall survival from initial diagnosis was 27 months. 1-year survival from first diagnosis was 83%, 2-year survival 45%. The median time to progression from the end of initial irradiation to recurrence was 12 months. 1-year PFS before reirradiation was 40%.
Conclusion:
hFSRT as a secondary treatment of recurrent GBM is a feasible and effective treatment option. Only minor side effects were observed with prolonged life expectancy of 9 months.
Hintergrund und Ziel:
Die Prognose im Rezidivfall eines malignen Glioms ist schlecht. Diese Studie hatte zum Ziel, den Stellenwert einer hypofraktionierten stereotaktischen Rebestrahlung (hFSRT) bei rezidiviertem Glioblastom (GBM) nach perkutaner hochkonformaler Radiotherapie zu evaluieren.
Patienten und Methodik:
Zwischen 1998 und 2008 wurden 53 Patienten mit einem rezidivierten GBM stereotaktisch rebestrahlt. Die mediane Gesamtherddosis betrug 30 Gy (20–60 Gy), die mediane Einzelherddosis 3 Gy/Tag (2–5 Gy).
Ergebnisse:
Trotz großer Tumorvolumen von median 35,01 ml wurde nach hFSRT keine Akut- oder Spättoxizität > Grad 2 beobachtet. Der Karnofsky-Perfomance-Score war der einzige determinante Faktor hinsichtlich des Gesamtüberlebens nach hFSRT (p = 0,0159). Hingegen beeinflussten Tumorvolumen (p = 0,4690), Patientenalter (p = 0,4301), Zweitoperationen (p = 0,6930) oder Chemotherapie (p = 0,1466) das Gesamtüberleben nach hFSRT nicht. Das mediane Gesamtüberleben nach hFSRT betrug 9 Monate, das progressionsfreie 1-Jahres-Überleben (PFS) 22%. Das mediane Gesamtüberleben nach initialer Diagnosestellung eines GBM lag bei 27 Monaten, das 1- bzw. 2-Jahres-Gesamtüberleben bei 83% bzw. 45%. Der mediane Zeitpunkt bis zum ersten Rezidiv nach initialer Bestrahlung betrug 12 Monate, das 1-Jahres-PFS nach initialer Bestrahlung bis zum ersten Rezidiv 40%.
Schlussfolgerung:
Die hFSRT ist eine geeignete und effektive Behandlungsoption für rezidivierte GBM. Das mediane Gesamtüberleben nach hFSRT konnte bei geringer Nebenwirkungsrate um 9 Monate verlängert werden.
Similar content being viewed by others
References
Alexiou GA, Tsiouris S, Voulgaris S, et al. 99mTc-tetrofosmin brain SPECT for target volume delineation in radiotherapy of high-grade gliomas. Letter on Krengli M, Loi G, Sacchetti G, et al. Delineation of target volume for radiotherapy of high-grade gliomas by 99mTc-MIBI SPECT and MRI fusion, in Strahlenther Onkol 2007;183:689-94 (No. 12) (DOI 10.1007/s00066-0071750-x). Strahlenther Onkol 2008;184:332–33.
Chan TA, Weingart JD, Parisi M, et al. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 2005;62:1133–9.
Chavaudra J. [Last ICRU recommendations for the prescription, recording and reporting of external bean therapy.] Cancer Radiother 1998;2:607–14.
Cho KH, Hall WA, Gerbi BJ, et al. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 1999;45:1133–41.
Combs SE, Gutwein S, Schulz-Ertner D, et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol 2005;181:372–7.
Combs SE, Thilmann C, Edler L, et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 2005;23:8863–9.
Combs SE, Widmer V, Thilmann C, et al. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 2005;104:2168–73.
Duchstein S, Gademann G, Peters B. Early and late effects of local high dose radiotherapy of the brain on memory and attention. Strahlenther Onkol 2003;179:441–51.
Ernst-Stecken A, Ganslandt O, Lambrecht U, et al. Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol 2007;81:287–94.
Geyer P, Blank H, Evers C, et al. Filmless evaluation of the mechanical accuracy of the isocenter in stereotactic radiotherapy. Strahlenther Onkol 2007;183:76–80.
Gross MW, Spahn U, Engenhart-Cabillic R. Assessment of the accuracy of a conventional simulation for radiotherapy of head and skull base tumors. Technol Cancer Res Treat 2003;2:345–51.
Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:511–9.
Henzel M, Hamm K, Gross MW, et al. Fractionated stereotactic radiotherapy of glomus jugulare tumors. Local control, toxicity, symptomatology, and quality of life. Strahlenther Onkol 2007;183:557–62.
Hudes RS, Corn BW, Werner-Wasik M, et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 1999;43:293–8.
Kocher M, Frommolt P, Borberg SK, et al. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol 2008;184:572–9.
Kohshi K, Yamamoto H, Nakahara A, et al. Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas. J Neurooncol 2007;82:297–303.
Kortmann RD, Jeremic B, Weller M, et al. Radiochemotherapy of malignant glioma in adults. Clinical experiences. Strahlenther Onkol 2003;179:219–32.
Larson DA, Prados M, Lamborn KR, et al. Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys 2002;54:1397–404.
Lederman G, Wronski M, Arbit E, et al. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 2000;23:155–9.
Lopatta E, Liesenfeld SM, Bank P, et al. Improved patient repositioning accuracy by integrating an additional jaw fixation into a high precision face mask system in stereotactic radiotherapy of the head. Strahlenther Onkol 2003;179:571–5.
Nieder C, Adam M, Molls M, et al. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 2006;60:81–193.
Nieder C, Astner ST, Mehta MP, et al. Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 2008;31:300–5.
Shepherd SF, Laing RW, Cosgrove VP, et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 1997;37:393–8.
Shrieve DC, Alexander E 3rd, Wen PY, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995;36:275–82, discussion 282-4.
Simon JM, Cornu P, Boisserie G, et al. Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 2002;53:67–74.
Stupp R. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;18:Suppl 2:ii69–70.
Stupp R, Hegi ME, Gilbert MR, et al. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007;25:4127–36.
Stupp R, Hottinger AF. Management of malignant glioma - quo vadis? Onkologie 2008;31:300–2.
Stupp R, Pica A, Mirimanoff RO, et al. [A practical guide for the management of gliomas.] Bull Cancer 2007;94:817–22.
Stupp R, Roila F. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19:Suppl 2:ii83–5.
Van Kampen M, Engenhart-Cabillic R, Debus J, et al. The radiosurgery of glioblastoma multiforme in cases of recurrence. The Heidelberg experiences compared to the literature. Strahlenther Onkol 1998;174:19–24.
Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 2005;5:55.
Author information
Authors and Affiliations
Corresponding author
Additional information
Both authors contributed equally to the study.
Rights and permissions
About this article
Cite this article
Fokas, E., Wacker, U., Gross, M.W. et al. Hypofractionated Stereotactic Reirradiation of Recurrent Glioblastomas. Strahlenther Onkol 185, 235–240 (2009). https://doi.org/10.1007/s00066-009-1753-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-009-1753-x